Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous MAGE-C2-specific HLA-A2-restricted TCR T lymphocytes

A preparation of autologous T lymphocytes genetically modified to express a T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A2-restricted, melanoma-associated antigen C2 (MAGE-C2; MC2), ALK epitope, with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with an anti-MAGE-C2-HLA-A2 restricted TCR, expanded ex vivo, and reintroduced into the HLA-A2-positive patient. Upon reintroduction, the autologous MAGE-C2-specific HLA-A2-restricted TCR T lymphocytes bind to tumor cells expressing the MAGE-C2 antigen, which may induce cell death in and halt the growth of MAGE-C2-expressing cancer cells. MAGE-C2, a cancer/testis tumor-associated antigen (CT-TAA), is overexpressed by a variety of cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous MAGE-C2/HLA-A2 TCR T cells
autologous MC2 TCR T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search